Karen Knudsen, Chief Executive Officer and Executive Director of Parker Institute for Cancer Immunotherapy, shared Network Bio’s post on LinkedIn, adding:
“Thrilled about this long awaited launch and supporting 2 brilliant founders.
Network Bio is taking up the challenge to connect biological data across institutions so we can better understand disease and develop precise treatments, faster.
Excited to be part of the team and to help shape what comes next!”
Quoting Network Bio’s post:
“Network Bio launches today with $50 million in financing from S32, Thiel Capital, Founders Fund, Breyer Capital, The Blue Venture Fund, JSL Health Capital and other leading life science and AI investors.
Network Bio is building a research network of leading U.S. academic biobanks to create AI models trained directly on human biology, combining patient-derived tissue, paired blood samples, molecular data and longitudinal clinical outcomes at unprecedented scale.
We also announced a collaboration with NVIDIA to develop the world’s first foundation model trained on cell-free RNA, combining Network Bio’s proprietary biological datasets with NVIDIA accelerated computing.
Network Bio already has a $30M+ co-development and licensing agreement with a Fortune 100 company, providing early commercial validation for its platform.
CEO and Co-Founder Asad Ali Ahmad said:
‘Every patient leaves a barcode of their disease in their tissue, and until now no one has been able to read those barcodes at scale.’
‘We built Network Bio based on the belief that AI and data hold the keys to advancing the human condition. We have been focused tirelessly on the dual mandate of gaining access to the tissue datasets which explain disease and building the AI systems capable of interpreting the complex results.’
said Network Bio co-founders Raphael Potter and Hani Goodarzi.
Congratulations to the team, Chairman Michael Pellini (former CEO of Foundation Medicine), Karen Knudsen, Morgan Cheatham and the entire Network Bio team, investors and partners on this milestone!
Read the The Wall Street Journal exclusive.
Read our NVIDIA collaboration.
Other articles featuring Karen Knudsen on OncoDaily.